Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06350981
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2024-06-13
First Post:
2024-03-15
Brief Title:
Analgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion
Sponsor:
Foundation for Orthopaedic Research and Education
Organization:
Foundation for Orthopaedic Research and Education
Study Overview
Official Title:
Analgesic Requirement for Post-Operative Pain Control in Elective 1-3 Level Transforaminal Lumbar Interbody Fusion Comparison of Thoracolumbar Interfascial Plane Block With Exparel to Bupivacaine HCl
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trail is to to compare the efficacy of thoracolumbar interfascial plane block with Exparel vs with standard of care 025 Bupivacaine HCl in patients undergoing 1-3 level elective transforaminal lumbar interbody fusion The investigators hypothesize that thoracolumbar interfascial plane block with Exparel will outperform standard of care supplemented with interfascial plane block of 025 Bupivacaine HCl with regards to pain reduction narcotic use length of hospital stay time to mobilization with physical therapy narcotic usage in the hospital and post operative pain scores
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None